RT Journal Article
SR Electronic
T1 One effect and two causes: Growth acceleration and breast cancer risk after hormone replacement therapy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.02.16.24302914
DO 10.1101/2024.02.16.24302914
A1 Hölzel, Dieter
A1 Schlesinger-Raab, Anne
A1 Halfter, Kathrin
YR 2024
UL http://medrxiv.org/content/early/2024/02/17/2024.02.16.24302914.abstract
AB Background An increased risk for breast cancer (BC) following hormone replacement therapy (HT) with estrogen and progesterone in women has been reported in several studies. However, HTs are associated with two distinct effects, a BC risk (RF) and an acceleration of BC growth (GAF). The interaction of both effects is analyzed.Methods Using data from the U.S. population on BC incidence and life expectancy specific cohorts and their disease trajectories are modelled. First, age-specific BCs are randomly generated for the age interval 50-80 years based on public data. Second, this simulated cohort subsequently receives a HT over 4 years that accelerates the growth of prevalent BCs. In a third cohort additional BCs are simulated caused by HT under treatment. The cumulative incidence of BCs is modelled for up to 30 years using different assumptions on BC growth duration, GAF and RF, as well as the duration of HT. The Women’s Health Initiative Study (WHI-S) is also simulated in a fourth cohort assuming a GAF 1.4 and RF 2.0.Results Studies modelling the risk of BC after HT imply two main findings: First, the growth of prevalent BCs is accelerated in parallel to the start of HT. This results in an increased BC incidence where the relative risk is equivalent to the GAF. The duration of HT defines the turning point of this increase. The second finding demonstrates that during the 15 years of BC growth an inherent RF for BC through HTs becomes observable only after a comparable delay. The combined effect results in an overlap of age-specific BCs, which develop at the same time, both growing faster under HT.Varying parameters can explain different results in the WHI-S. According to the WHI almost 6 million women decided to discontinue or not to start HT. This offers a valid explanation (assuming a GAF 2) for the 10% decline in incidence around 2002. Estimates which report one million additional BCs associated with HT in Western countries since 1990 can thus, for the most part, be attributed to more rapidly growing prevalent BCs.Conclusion HT accelerates the growth of prevalent BCs and can also cause BCs which become symptomatic after 10 or more years. In combination these effects increase BC incidence. Differentiated information on these inherent risks and benefits should support shared decision-making for HT.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used only openly available human data that were originally located at: http://seer.cancer.gov/ https://seer.cancer.gov/statistics-network/ http://www.tumorregister-muenchen.de/en/facts/specific_analysis.phpI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced are available online at: http://seer.cancer.gov/ https://seer.cancer.gov/statistics-network/ http://www.tumorregister-muenchen.de/en/facts/specific_analysis.php http://seer.cancer.gov/ https://seer.cancer.gov/statistics-network/ http://www.tumorregister-muenchen.de/en/facts/specific_analysis.php BCBreast cancerGDGrowth duration of BCsGAFGrowth acceleration factorHTHormone replacement therapyHTDHormone replacement therapy durationHR+/-Hormone receptor positive/negativeMETMetastasis, metastasesMWSMillion Women StudRFBC risk factorRRrelative riskVDTVolume doubling timeWHI-SWomen’s Health Initiative Studies